TrumpRx? Pfizer, Drugmakers AGREE To LOWER Drug Prices For MEDICAID Recipients | TRENDING
September 30, 2025
1,467
19
6
1.70%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
The Hill Episodes Around September 30, 2025
See what was published immediately before and after this episode.
3:52Now PlayingTrumpRx? Pfizer, Drugmakers AGREE To LOWER Drug Prices For MEDICAID Recipients | TRENDING
YouTube Description
as posted by the channelPresident Trump on Tuesday announced that Pfizer had agreed to sell its products in the U.S. at “Most Favored Nation” pricing, one day after the administration required companies to respond to his prescription drug pricing executive order.
Drugmakers were given until Sept. 29 to respond to Trump’s “Most Favored Nation” Executive Order that required companies sell drugs in the U.S. at the lowest price they sell in other developed countries, establish direct-to-consumer avenues and not sell new drugs for lower prices in other countries.
“Pfizer is committing to offer all of their prescription medications to Medicaid. it will be at the most favored nation’s prices. It’s going to have a huge impact on bringing Medicaid costs down like nothing else,” Trump said in a press briefing in the Oval Office.
Trump had sent requests to 16 other drugmakers in his executive order. It’s unclear if others will follow Pfizer’s lead. Some of the companies told The Hill on Monday they remained in discussions with the administration.
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.